Relevant bibliographies by topics / End stage kidney disease / Books

Books on the topic 'End stage kidney disease'

To see the other types of publications on this topic, follow the link: End stage kidney disease.
Author: Grafiati
Published: 4 June 2021
Last updated: 25 May 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'End stage kidney disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

State University of New York at Albany. School of Public Health. End Stage Renal Disease in New York State. Albany, NY: Health Research, Inc., 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Joseph, Loscalzo, and London Gérard M, eds. Cardiovascular disease in end-stage renal failure. Oxford: Oxford University Press, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Friedman, Eli A. Present and future therapies for end-stage renal disease. New Jersey: World Scientific, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

1933-, Friedman Eli A., and Mallappallil Mary C, eds. Present and future therapies for end-stage renal disease. New Jersey: World Scientific, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jassal, Sarbjit Vanita. Kidney transplantation in elderly patients with end-stage renal disease. Ottawa: National Library of Canada, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Library of Congress. Congressional Research Service, ed. Medicare's end stage renal disease program. [Washington, D.C.]: Congressional Research Service, Library of Congress, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

1938-, Hardy Mark A., and Kutscher Lillian G, eds. Positive approaches to living with end stage renal disease: Psychosocial and thanatologic aspects. New York: Praeger, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Federal-Provincial Advisory Committee on Institutional and Medical Services (Canada). Subcommittee on Institutional Program Guidelines. End-stage renal disease program: Report. Ottawa: Health and Welfare Canada, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Halper, Thomas. The misfortunes of others: End-stage renal disease in the United Kingdom. Cambridge: Cambridge University Press, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

United States. Agency for Health Care and Policy Research. Laboratory tests in end-stage renal disease patients undergoing dialysis. Rockville, Md: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

Green, Ira. Laboratory tests in end-stage renal disease patients undergoing dialysis. Rockville, Md: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Green, Ira. Laboratory tests in end-stage renal disease patients undergoing dialysis. Rockville, Md: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Green, Ira. Laboratory tests in end-stage renal disease patients undergoing dialysis. Rockville, Md: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Green, Ira. Laboratory tests in end-stage renal disease patients undergoing dialysis. Rockville, Md: U.S. Dept. of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Council on Community Health, Hospital, Institutional, and Medical Affairs. Ad Hoc Committee on Protocol Development. Patients with end-stage renal disease. Chicago, Ill: American Dental Association, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Florida. Legislature. House of Representatives. Committee on Health Regulation. Overview of kidney dialysis studies and providers of end stage renal disease care. [Tallahassee, Fla.]: The Committee, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
17

1938-, Hardy Mark A., ed. Psychosocial aspects of end-stage renal disease: Issues of our times. New York: Haworth Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

V, Wizemann, Kramer W, and Schütterle G, eds. The heart in end-stage renal failure: Etiology, symptoms, and management of uremic heart disease. Basel: Karger, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
19

United States. Health Care Financing Administration. Bureau of Data Management and Strategy., ed. End Stage Renal Disease Program: Instruction manual for renal providers. Baltimore, Md: Dept. of Health and Human Services, Health Care Financing Administration, Bureau of Data Management and Strategy, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
20

Dimosthenis, Stamopoulos, ed. Magnetically assisted hemodialysis: A new strategy for the treatment of end stage renal disease. New York: Nova Science Publishers, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
21

M, Ross Linda, ed. Kidney and urinary tract diseases and disorders sourcebook: Basic information about kidney stones, urinary incontinence, bladder disease, end stage renal disease, dialysis, and more, along with statistical and demographic data and reports on current research initiatives. Detroit, MI: Omnigraphics, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
22

Held, Philip J. Costs, competition, and outcomes in the End-Stage Renal Disease Program. Washington, D.C: Urban Institute, Health Policy Center, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
23

A, Rettig Richard, and Levinsky Norman G. 1929-, eds. Kidney failure and the federal government. Washington, D.C: National Academy Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
24

G, Oreopoulos D., and International Symposium on Geriatric Nephrology, eds. Geriatric nephrology: The medical, psychosocial, nursing, financial, and ethical issues of treating end-stage renal disease in the elderly. Dordrecht: Nijhoff, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
25

Handelsman, Harry. Hemoperfusion in conjunction with deferoxamine for the treatment of aluminum toxicity or iron overload in patients with end-stage renal disease. Rockville, MD: National Center for Health Services Research and Health Care Technology Assessment, U.S. Dept. of Health and Human Services, Public Health Service, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
26

Handelsman, Harry. Hemoperfusion in conjunction with deferoxamine for the treatment of aluminum toxicity or iron overload in patients with end-stage renal disease. Rockville, MD: National Center for Health Services Research and Health Care Technology Assessment, U.S. Dept. of Health and Human Services, Public Health Service, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
27

United States. Congress. House. Committee on Ways and Means. Subcommittee on Health. Medicare End-Stage Renal Disease (kidney failure) Program: Hearing before the Subcommittee on Health of the Committee on Ways and Means, House of Representatives, One Hundred Fourth Congress, first session, April 3, 1995. Washington: U.S. G.P.O., 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
28

United States. Health Care Financing Administration. Office of Research and Demonstrations., ed. End-stage renal disease, 1985. Baltimore, Md: U.S. Dept. of Health and Human Services, Health Care Financing Administration, Bureau of Data Management and Strategy, Office of Research and Demonstrations, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
29

United States. Health Care Financing Administration. Bureau of Data Management and Strategy. End stage renal disease, 1993-95. Baltimore, Md: Dept. of Health and Human Services, Health Care Financing Administration, Bureau of Data Management and Strategy, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
30

1935-, Walter P. J., ed. Treatment of end-stage coronary artery disease. Basel: Karger, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

Kenora-Rainy River District Health Council. End stage renal disease task force report. [s.l.]: Kenora-Rainy River District Health Council, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
32

United States. Health Care Financing Administration., ed. End stage renal disease Program highlights 1992. [Washington, D.C.?]: Health Care Financing Administration, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
33

Murtagh, Fliss E. M. End-stage kidney disease. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0156.

Full text
Abstract:
End-stage kidney disease (ESKD) accounts for 1-2% of all deaths. Ageing populations means that this proportion will grow steadily over the coming years. Symptom burden in ESKD exceeds advanced cancer, with added renal-specific symptoms, such as itch and restless legs. Pain and depression are also more prevalent. Many renal symptoms go under-recognized and under-treated, especially as they arise from co-morbid conditions, rather than the renal disease itself. The most useful intervention to address symptoms is regular assessment of symptoms, using a valid and reliable global symptom score. Pharmacological interventions to alleviate symptoms need to take account of the severe constraints on using renally cleared drugs, and the high risk of toxicity from accumulation of parent compound or metabolites. The population with ESKD has extensive palliative care needs, and need significant medical, nursing, psychological, and social care to address these as their illness advances towards the end of life.
APA, Harvard, Vancouver, ISO, and other styles
34

Rabin, Pauline L., and William J. Stone. End-Stage Renal Disease: An Integrated Approach. Elsevier Science & Technology Books, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
35

Haddad, Maha N., Erica Winnicki, and Stephanie Nguyen. Adolescents with Chronic Kidney Disease: From Diagnosis to End-Stage Disease. Springer, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
36

Haddad, Maha N., Erica Winnicki, and Stephanie Nguyen. Adolescents with Chronic Kidney Disease: From Diagnosis to End-Stage Disease. Springer, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
37

Sevelamer in patients with end-stage renal disease: A systematic review and economic evaluation. Ottawa: Canadian Agency for Drugs and Technologies in Health, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
38

Halper, Thomas. Misfortunes of Others: End-Stage Renal Disease in the United Kingdom. Cambridge University Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
39

Winston, Jonathan, Etti Zeldis, John A. Grimaldi, and Esteban Martínez. HIV-Associated Nephropathy, End-Stage Renal Disease, Dialysis, and Kidney Transplant. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0044.

Full text
Abstract:
Antiretroviral therapy has changed the phenotype of HIV-related kidney disease to a more chronic disease model. In addition to HIV-associated nephropathy (HIVAN), patients with HIV may experience kidney dysfunction related to other chronic illnesses, such as diabetes, hypertension, and hepatitis C. Patients with HIV should be monitored for the development of chronic kidney disease and the potential nephrotoxicity of antiretroviral therapy. For patients with HIV who progress to end-stage renal disease, the outcomes on dialysis and management of the dialysis procedure are similar to the outcomes of patients without HIV. Renal transplantation is a promising treatment option for HIV patients with end-stage renal disease, despite certain barriers inherent in the transplant evaluation process. Concomitant HIV and end-stage renal disease, with the stress of dialysis, can exacerbate psychiatric illness.
APA, Harvard, Vancouver, ISO, and other styles
40

A clinical guide to nutrition care in end-stage renal disease. 2nd ed. Chicago, Ill: American Dietetic Association, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
41

A Clinical guide to nutrition care in end-stage renal disease. Chicago, Ill: American Dietetic Association, 1987.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
42

Theofilou, Paraskevi, ed. Outcomes Assessment in End - Stage Kidney Disease - Measurements and Applications in Clinical Practice. BENTHAM SCIENCE PUBLISHERS, 2013. http://dx.doi.org/10.2174/97816080573511130101.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Bello, Aminu, Marcello Tonelli, and Kitty Jager. Epidemiology of kidney disease. Edited by Christopher G. Winearls. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0001.

Full text
Abstract:
Renal epidemiology has moved from a focus on patients treated with renal replacement therapy using data from renal registries, to a much broader view of acute and chronic kidney disease. A review of essential epidemiological concepts and principles is followed by discussion of the epidemiology of different types of kidney disease: acute kidney injury, chronic kidney disease, and end-stage renal disease. The chapter concludes with a section on future challenges and potential solutions.
APA, Harvard, Vancouver, ISO, and other styles
44

Haynes, Richard J., and James A. Gilbert. Chronic kidney disease and dialysis. Edited by Rutger Ploeg. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0128.

Full text
Abstract:
Chronic kidney disease (CKD) is a common disorder as currently defined. Patients with CKD face two major hazards: cardiovascular disease and—in a minority—progression to end-stage renal disease (ESRD). Advanced CKD also causes numerous metabolic and other complications. The management of CKD involves excluding acute kidney injury, diagnosing the cause of CKD, slowing progression, and detecting and treating complications. If patients do reach ESRD, then renal replacement therapy (RRT) options must be considered. These include haemodialysis, peritoneal dialysis, or transplantation. Haemodialysis requires creation of an arteriovenous fistula or insertion of a prosthetic graft while peritoneal dialysis necessitates the insertion of a catheter into the abdominal cavity. All forms of dialysis access are associated with complications both in the short and long term. However, they remain vital and central to the life and the well-being of the end-stage renal patient on dialysis.
APA, Harvard, Vancouver, ISO, and other styles
45

(Editor), Mark A. Hardy, Gerald B. Appel (Editor), John M. Kiernan (Editor), Austin H. Kutscher (Editor), Martha L. Orr (Editor), Carol Smith Torres (Editor), and Lissa Parsonnet (Editor), eds. Positive Approaches to Living with End Stage Renal Disease: Psychosocial and Thanatalogic Aspects (The Foundation of Thanatology Series). Praeger Publishers, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
46

Erickson, Stephen B., Hatem Amer, and Timothy S. Larson. Urolithiasis, Kidney Transplantation, and Pregnancy and Kidney Disease. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199755691.003.0475.

Full text
Abstract:
It was previously assumed that all kidney stones crystallized as urine passed through the renal tubules and were retained by means of crystal-tubular cell interactions. Recently uroscopy with papillary biopsies has shown 2 different pathways for stone formation, both mediated by calcium phosphate crystals. Kidney transplant has become the preferred treatment for patients with end-stage renal disease. Those benefiting from transplant included patients who would be deemed "high risk," such as those with diabetes mellitus and those older than 70 years. Anatomical changes associated with pregnancy are renal enlargement and dilatation of the calyces, renal pelvis, and ureters. Physiologic changes include a 30% to 50% increase in glomerular filtration rate and renal blood flow; a mean decrease of 0.5 mg/dL in the creatinine level and a mean decrease of 18 mg/dL in the serum urea nitrogen level; intermittent glycosuria independent of plasma glucose; proteinuria; aminoaciduria; increased uric acid excretion; increased total body water, with osmostat resetting; 50% increase in plasma volume and cardiac output; and increased ureteral peristalsis.
APA, Harvard, Vancouver, ISO, and other styles
47

Yaqoob, Muhammad M. Acidosis in chronic kidney disease. Edited by David J. Goldsmith. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0148.

Full text
Abstract:
Metabolic acidosis becomes increasingly common as chronic kidney disease progresses. It is associated with a number of complications, including bone disease, altered protein synthesis and degradation, skeletal muscle wasting, and lately progressive glomerular filtration rate loss. Experimental and clinical studies suggest a role for alkali therapy to lessen these complications. Recent controlled studies support this notion, and suggest that correction of metabolic acidosis in patients with chronic kidney disease slows the rate of decline of renal function and the development of end-stage renal disease, although more definitive evidence is needed on the long-term benefits of alkali therapy, type of alkali supplements, and the optimal level of serum bicarbonate.
APA, Harvard, Vancouver, ISO, and other styles
48

Ong, Albert C. M., and Richard Sandford. Autosomal dominant polycystic kidney disease. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0306_update_001.

Full text
Abstract:
Based on an estimated population prevalence of between 1 in 400 and 1 in 1000, there are over 60,000 individuals with or at risk of developing complications associated with autosomal dominant polycystic kidney disease (ADPKD) in the United Kingdom. This equates to over 300,000 people in the United States and 7 million worldwide. Once diagnosed, an individual with ADPKD will require long-term medical follow-up and treatment with an unknown cost to national health care systems. A major proportion, probably two-thirds, will develop end-stage renal disease (ESRD) requiring renal replacement therapy—dialysis or transplantation. ADPKD is therefore the commonest genetic cause of ESRD. Most centres worldwide report that approximately one in ten patients receiving dialysis therapy have a diagnosis of ADPKD. Improvements in healthcare for individuals with ADPKD will therefore impact directly on patients, their families, and healthcare resources.
APA, Harvard, Vancouver, ISO, and other styles
49

(Editor), Linda M. Ross, and Peter Dresser (Editor), eds. Kidney and Urinary Tract Diseases and Disorders Sourcebook: Basic Information About Kidney Stones, Urinary Incontinence, Bladder Disease, End Stage Renal ... Statistical and (Health Reference Series). Omnigraphics, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
50

Ong, Albert C. M., and Timothy Ellam. Autosomal dominant polycystic kidney disease. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0307_update_001.

Full text
Abstract:
Autosomal dominant polycystic kidney disease (ADPKD) is responsible for up to 10% of prevalent patients with end-stage renal disease (ESRD). It is characterized by the enlargement of multiple bilateral renal cysts, present in almost all patients by their fifth decade. Loin pain is a common symptom that may be caused by cyst growth, intracyst haemorrhage, nephrolithiasis, or infection. Gross haematuria is also a common feature, but usually settles spontaneously. Excretory impairment develops after extensive cystic change has occurred and progresses to ESRD in half of all affected patients by the age of 60. However, the onset of cystic change and rate of renal functional decline are highly variable between individuals. ADPKD associated with the PKD1 gene has an earlier average age of cyst development and ESRD than PKD2, but the two cannot be distinguished on clinical grounds. Polycystins 1 and 2 are expressed in various organs and extrarenal disease may be the presenting feature. Intracranial aneurysms are five times more common in patients with ADPKD, but rupture is infrequent. Liver cysts are present in most patients and may be complicated by haemorrhage or infection, though liver failure is very rare. Massive hepatic cystic disease is confined to women, reflecting stimulatory effects of oestrogen on hepatic cyst growth. Cardiovascular disease is the leading cause of death in ADPKD and vascular dysfunction is present in many patients even before the development of excretory impairment. However, despite the multisystem manifestations of ADPKD, survival from ESRD is better for patients with ADPKD than for other non-diabetic causes of kidney failure.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'End stage kidney disease' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography